Anhui Anke BioTech Group (300009) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anhui Anke BioTech Group (300009) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥240.51 Million ≈ $35.19 Million USD) by net assets (CN¥4.34 Billion ≈ $635.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300009 market cap for the company's overall valuation and market capitalisation.
Anhui Anke BioTech Group - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Anhui Anke BioTech Group's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anhui Anke BioTech Group Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anhui Anke BioTech Group ranked by their cash flow conversion efficiency. Explore Anhui Anke BioTech Group cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
0.048x |
|
Telecom Argentina
BA:TECO2
|
0.156x |
|
Jindal Saw Limited
NSE:JINDALSAW
|
-0.025x |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
0.022x |
|
Batu Kawan Bhd
KLSE:1899
|
-0.060x |
|
Hangzhou Steam Turbine
SHE:200771
|
0.014x |
|
BWP Trust
AU:BWP
|
0.020x |
|
Sichuan Teway Food Group Co Ltd
SHG:603317
|
0.081x |
Annual Cash Flow Conversion Efficiency for Anhui Anke BioTech Group (2006–2025)
The table below shows the annual cash flow conversion efficiency of Anhui Anke BioTech Group from 2006 to 2025. View Anhui Anke BioTech Group share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.74 Billion ≈ $693.08 Million |
CN¥863.22 Million ≈ $126.32 Million |
0.182x | +14.34% |
| 2024-12-31 | CN¥4.30 Billion ≈ $629.22 Million |
CN¥685.37 Million ≈ $100.29 Million |
0.159x | -34.23% |
| 2023-12-31 | CN¥3.93 Billion ≈ $575.42 Million |
CN¥952.97 Million ≈ $139.45 Million |
0.242x | +17.94% |
| 2022-12-31 | CN¥3.40 Billion ≈ $497.77 Million |
CN¥698.98 Million ≈ $102.28 Million |
0.205x | +0.75% |
| 2021-12-31 | CN¥2.90 Billion ≈ $424.88 Million |
CN¥592.17 Million ≈ $86.65 Million |
0.204x | +28.50% |
| 2020-12-31 | CN¥2.93 Billion ≈ $428.54 Million |
CN¥464.80 Million ≈ $68.01 Million |
0.159x | +44.95% |
| 2019-12-31 | CN¥2.70 Billion ≈ $395.10 Million |
CN¥295.63 Million ≈ $43.26 Million |
0.109x | -23.41% |
| 2018-12-31 | CN¥2.01 Billion ≈ $294.29 Million |
CN¥287.49 Million ≈ $42.07 Million |
0.143x | -10.32% |
| 2017-12-31 | CN¥1.76 Billion ≈ $257.60 Million |
CN¥280.63 Million ≈ $41.06 Million |
0.159x | -11.88% |
| 2016-12-31 | CN¥1.43 Billion ≈ $208.70 Million |
CN¥258.01 Million ≈ $37.75 Million |
0.181x | +92.66% |
| 2015-12-31 | CN¥1.26 Billion ≈ $185.03 Million |
CN¥118.73 Million ≈ $17.37 Million |
0.094x | -33.17% |
| 2014-12-31 | CN¥773.47 Million ≈ $113.18 Million |
CN¥108.68 Million ≈ $15.90 Million |
0.141x | +74.44% |
| 2013-12-31 | CN¥660.60 Million ≈ $96.67 Million |
CN¥53.21 Million ≈ $7.79 Million |
0.081x | -13.16% |
| 2012-12-31 | CN¥580.03 Million ≈ $84.88 Million |
CN¥53.80 Million ≈ $7.87 Million |
0.093x | +602.56% |
| 2011-12-31 | CN¥543.88 Million ≈ $79.59 Million |
CN¥7.18 Million ≈ $1.05 Million |
0.013x | -85.46% |
| 2010-12-31 | CN¥522.30 Million ≈ $76.43 Million |
CN¥47.43 Million ≈ $6.94 Million |
0.091x | +16.32% |
| 2009-12-31 | CN¥495.41 Million ≈ $72.49 Million |
CN¥38.67 Million ≈ $5.66 Million |
0.078x | -55.44% |
| 2008-12-31 | CN¥148.64 Million ≈ $21.75 Million |
CN¥26.04 Million ≈ $3.81 Million |
0.175x | -31.56% |
| 2007-12-31 | CN¥137.09 Million ≈ $20.06 Million |
CN¥35.10 Million ≈ $5.14 Million |
0.256x | +5.30% |
| 2006-12-31 | CN¥122.00 Million ≈ $17.85 Million |
CN¥29.66 Million ≈ $4.34 Million |
0.243x | -- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more